RAHWAY, N.J., May 7, 2026
Merck announced the publication of a landmark scientific paper in the journal Science detailing a novel large-scale biocatalytic manufacturing method for enlicitide decanoate, the company’s investigational oral PCSK9 inhibitor designed for lowering LDL cholesterol. The publication outlines a highly advanced enzymatic synthesis platform capable of manufacturing complex macrocyclic peptide therapeutics at scale, representing a major breakthrough in pharmaceutical manufacturing science and cardiovascular drug development. The company stated that the new process could significantly improve sustainability, manufacturing efficiency, and long-term accessibility of next-generation oral peptide medicines. Enlicitide has attracted industry attention due to its potential to become the first approved oral PCSK9 inhibitor, offering a pill-based alternative to currently marketed injectable PCSK9 therapies used for cholesterol management and prevention of atherosclerotic cardiovascular disease (ASCVD).
Merck Advances Biocatalytic Manufacturing for Macrocyclic Peptides
According to the publication, Merck scientists developed a specialized biocatalytic synthesis platform utilizing a tailored suite of enzymes capable of performing selective peptide fragment assembly, coupling reactions, and macrocyclization steps required for the production of enlicitide. The company explained that traditional synthetic chemistry approaches were insufficient for manufacturing such a structurally complex macrocyclic peptide at commercial scale. By integrating enzymatic catalysis with highly efficient crystallization purification methods, researchers successfully created a scalable and environmentally sustainable manufacturing process that could potentially serve as a blueprint for future oral peptide therapeutics.
Merck emphasized that biocatalysis offers substantial environmental and operational advantages compared with conventional chemical synthesis, including reduced waste generation, lower energy consumption, improved selectivity, and enhanced manufacturing efficiency. The company noted that it has invested in enzyme engineering and industrial biocatalysis research for more than 25 years as part of its broader pharmaceutical innovation strategy. The publication in Science highlights the growing role of advanced manufacturing technologies in supporting complex drug development pipelines, particularly for biologics-inspired small molecule therapies and macrocyclic peptide platforms.
Dean Y. Li, president of Merck Research Laboratories, stated that macrocyclic peptides may unlock new opportunities to create oral medicines capable of targeting difficult disease pathways traditionally accessible only through injectable biologic therapies. He added that the scalable production process described in the publication demonstrates Merck’s scientific capabilities and supports the company’s long-term commitment to addressing the global cardiovascular disease epidemic through innovative treatment strategies.
Advertisement
Enlicitide Targets PCSK9 Through Oral Daily Dosing
Enlicitide is a macrocyclic peptide therapeutic candidate designed to inhibit PCSK9, a protein that plays a central role in cholesterol regulation by controlling the availability of LDL receptors responsible for clearing LDL cholesterol from the bloodstream. Current FDA-approved PCSK9 inhibitors are monoclonal antibody therapies administered through injection. Merck’s investigational oral approach aims to deliver comparable biological activity in the form of a once-daily pill, potentially improving patient convenience, treatment adherence, and broader access to cholesterol-lowering therapy.
The company explained that enlicitide works by binding to PCSK9 and preventing its interaction with LDL receptors, allowing increased receptor recycling and enhanced clearance of LDL cholesterol from circulation. PCSK9 inhibition has emerged as a major therapeutic strategy for reducing cardiovascular risk, particularly in patients with elevated LDL cholesterol levels or established ASCVD. Cardiovascular disease remains the leading cause of death globally, with ASCVD accounting for approximately 85% of cardiovascular-related deaths worldwide.
Publication Highlights Future of Oral Peptide Therapeutics
Industry experts continue to closely monitor the development of macrocyclic peptide medicines because of their unique ability to combine the target specificity and potency of biologic drugs with the convenience and scalability of oral small molecules. Merck stated that enlicitide represents the culmination of more than a decade of interdisciplinary research focused on designing orally bioavailable peptide therapeutics capable of disrupting complex protein-protein interactions. The scalable synthesis process described in the publication may also have broader implications for the future development of oral peptide drugs across multiple therapeutic areas beyond cardiovascular disease.
The publication further reinforces the pharmaceutical industry’s increasing focus on integrating advanced manufacturing science, enzyme engineering, and sustainable chemistry into next-generation drug development programs. As global demand rises for more accessible cardiovascular therapies, scalable oral biologic-inspired medicines such as enlicitide may become an important future direction for both drug innovation and commercial manufacturing.
Source: Merck press release
